Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Enable superior drug development and patient care decision-making through model-informed drug development, regulatory science, real world evidence and knowledge integration, thus optimizing R&D productivity, commercial value and patient outcomes.

Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Latest from Certara

Blog

Optimize Immuno-oncology Drug Discovery and Development Using Quantitative Systems Pharmacology

Could Virtual Twin Technology Support Model-informed Precision Dosing?

Spotlight on the PAGE Student Sponsorship Winners 2019

In the Press

Certara Announces the Formation of a New Practice Area Focused on Global Health

Certara Announces First Recipients of Certara-Monash University Industry Drug Development Fellowships

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Webinars

Mechanisms of Physiological Changes in Drug Exposure in Cancer Patients

Innovative Solutions for Fast-Tracking Drugs for Rare Diseases

Changing the Game in Drug Development and Patient Access

Model-informed Drug Development Health Economics/Outcomes Research & Real World Evidence Regulatory Science, Strategy & Services

Certara Supported 90+ Percent of US FDA Novel New Drug Approvals for Fourth Consecutive Year

Certara’s Simcyp PBPK M&S Technology Achieves First FDA Virtual Bioequivalence Approval for ‘Complex’ Generic Drug

Our Mission

Latest from Certara

Changing the Game in
Drug Development and Patient Access

Model-informed Drug Development
Health Economics/Outcomes Research & Real World Evidence
Regulatory Science, Strategy & Services